Louis-Philippe Boulet1. 1. Institut de cardiologie et de pneumologie de l'Université Laval, Hôpital Laval, Quebec City, QC, Canada. lpboulet@med.ulaval.ca
Abstract
PURPOSE OF REVIEW: Inhaled corticosteroids (ICS) are the mainstay of asthma therapy. Although compliance to this type of medication is often suboptimal and once-daily dosing can help to improve adherence to the treatment, the clinical implications of such a mode of administration should be determined. RECENT FINDINGS: This review summarizes the recent studies on comparative efficacy of once-versus twice-daily administration of ICS, in light of previous reports. SUMMARY: Although twice-daily administration of ICS is often better to optimize asthma parameters, in many patients, asthma can be sufficiently controlled by a once-daily regimen of most ICS. An increased frequency of dosing seems preferable if asthma becomes uncontrolled or is severe, although this requires further study. A therapeutic trial should, however, be done to ensure that asthma control is adequate. Comparative long-term effects of such a strategy on inflammatory and remodeling parameters remain to be determined, as does the proportion of patients who can adequately control their asthma with once-daily administration of the various ICS available.
PURPOSE OF REVIEW: Inhaled corticosteroids (ICS) are the mainstay of asthma therapy. Although compliance to this type of medication is often suboptimal and once-daily dosing can help to improve adherence to the treatment, the clinical implications of such a mode of administration should be determined. RECENT FINDINGS: This review summarizes the recent studies on comparative efficacy of once-versus twice-daily administration of ICS, in light of previous reports. SUMMARY: Although twice-daily administration of ICS is often better to optimize asthma parameters, in many patients, asthma can be sufficiently controlled by a once-daily regimen of most ICS. An increased frequency of dosing seems preferable if asthma becomes uncontrolled or is severe, although this requires further study. A therapeutic trial should, however, be done to ensure that asthma control is adequate. Comparative long-term effects of such a strategy on inflammatory and remodeling parameters remain to be determined, as does the proportion of patients who can adequately control their asthma with once-daily administration of the various ICS available.
Authors: Ashley Woodcock; Eric D Bateman; William W Busse; Jan Lötvall; Neil G Snowise; Richard Forth; Loretta Jacques; Brett Haumann; Eugene R Bleecker Journal: Respir Res Date: 2011-10-06
Authors: Tanja T Menckeberg; Svetlana V Belitser; Marcel L Bouvy; Madelon Bracke; Jan-Willem J Lammers; Jan A M Raaijmakers; Hubert G M Leufkens Journal: BMC Health Serv Res Date: 2007-07-10 Impact factor: 2.655